Overview
EB-5 Green Cards Benefits
EB-5 Regional Center Benefits
Obtaining your Green Card

EB-5 Overview

The EB-5 Program and the New York Proton Regional Center

United States Congress created the Employment-Based Fifth (EB-5) immigrant investor Green Card program in 1990. The purpose of the EB-5 program is to encourage immigrants to invest in or to manage U.S. companies that benefit the U.S. economy.

Foreign investors are required to invest a minimum of $500,000 in a qualified Regional Center that will lead to the creation of ten or more new jobs.

As a designated Regional Center, New York Proton Regional Center’s funding will come from foreign investors. New York Proton Regional Center will raise the capital required to create a Proton Therapy Treatment Facility, including Radiology and Oncology Benefit Management programs, in New York City.

Additionally, the project will include the development of a Radiology and Oncology Benefit Management program.

If you are an investor whose goals include permanent residency in the United States for yourself and your immediate family, an investment in the New York Proton Regional Center could help you achieve your objectives and bring you one step closer to the American dream.



Tour our
up and coming state-of-the-art
research and
treatment center



.
Proton radiation treatment differs from standard radiation therapy. If given in sufficient doses, conventional radiation therapy techniques will control many cancers. However, because of the physician's inability to adequately conform the irradiation pattern to the cancer, healthy tissues may be damaged with radiation.
View a quick presentation of the science behind proton therapy.
Proton Beam Radiation Therapy: Balancing Evidence-Based Use with the Bottom Line
Proton Brings Hope
Cancer treatment utilizing proton therapy absolutely shows promise as the Hampton University Proton Institute
LOMA LINDA: Cincinnati man is 15,000th proton therapy patient



© New York Proton Regional Center 2011 All Rights Reserved Home Contact us Investor Relations F.A.Q.